Diagnosing coinfection in pneumonia can be challenging because of timing of the sample collection and false-negative results when the viruses replicate in the lower respiratory tract.
There appears to be a low risk of invasive fungal secondary infection, especially aspergillosis, in patients with SARS-CoV-2-related pneumonia and no underlying immunosuppression.
The authors described the cases of 3 patients with moderate to severe COVID-19 pneumonia who were treated with 2g of icosapent ethyl administered twice daily via a nasogastric tube.
Study authors assessed the efficacy and safety of cefiderocol vs best available therapy in adults with serious carbapenem-resistant Gram-negative infections.
Although hypercoagulability has been reported in critically ill patients with COVID-19, results from a small study revealed that these patients did not have a higher prevalence of pulmonary embolism compared to patients without COVID-19.
Study authors described the prescribing patterns in children with community-acquired pneumonia, and assessed the relationship between narrow-spectrum antibiotics, broad-spectrum antibiotics, and macrolides with clinical outcomes.
The effect of appropriate antimicrobial therapy on 14-day mortality in patients severely ill with Acinetobacter baumannii bacteremic pneumonia was assessed, taking risk factors, patient demographics, and clinical characteristics into account.
Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.
Study authors assessed pneumococcal urinary antigen testing’s use in identifying patients for broad-spectrum antibiotic de-escalation, providing an opportunity for improved antimicrobial stewardship.
Pneumomediastinum, although a rare phenomenon, is more prevalent in patients with COVID-19 compared with historical patients with adult respiratory distress syndrome.
Patients with severe COVID-19 pneumonia had improved prognosis after receiving a short course of methyl-prednisolone pulses during the second week of disease.
